Q-omics provides the consensus-scored TOPAZ1 profile across patient tissues and cancer cell-line models. TOPAZ1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TOPAZ1 is differentially expressed in 5, with the highest sampling consensus in KIRP. Additionally, TOPAZ1 RNA expression shows 7,779 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRP, and TGCT as cancer lineages where TOPAZ1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TOPAZ1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TOPAZ1 survival associations across molecular data types. TOPAZ1 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TOPAZ1 RNA expression–survival associations across cancer types. High TOPAZ1 expression shows unfavorable associations in UVM, LUSC, BRCA, THCA and BLCA, but favorable associations in UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TOPAZ1 RNA expression.
This table summarizes TOPAZ1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for TOPAZ1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TOPAZ1 shows lower tumor expression in KIRP, KICH and THCA and higher tumor expression in HNSC and LIHC. The KIRP box plot shows higher TOPAZ1 RNA expression in normal versus tumor tissue (log2 FC = −0.019, t-test p = .017).
This table shows molecular features associated with TOPAZ1 in patient tissues and cancer cell lines. In patient samples, TOPAZ1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TOPAZ1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
